Nanogel‐based delivery system enhances PGE2 effects on bone formation
- 22 May 2007
- journal article
- fast track
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 101 (5) , 1063-1070
- https://doi.org/10.1002/jcb.21160
Abstract
Recovery of bone loss is one of the active research issues in bone medicine due to the need for efficient measures for bone gain. We examined here a novel drug delivery system using a nanogel of cholesterol-bearing pullulan (CHP) in combination with prostaglandin E2 (PGE2). PGE2 or PGE2/CHP, vehicle (saline containing 0.06% ethanol and 0.02% Tween 80) or CHP were injected on to the calvariae of mice once every day for 5 days per week for 4 weeks. Low dosage of PGE2 (0.6 µg) alone or CHP alone did not induce new bone formation in this system. In contrast, PGE2 (0.6 µg)/CHP induced new bone formation. Bone formation activities of PGE2 was enhanced by CHP nanogels only at the site of injection (calvaria) but not in the distant sites of the skeleton, showing that PGE2/CHP could avoid systemic effects. In spite of the fact that previously reported animal models of bone formation by PGE2 were associated with loss of body weight, bone formation based on PGE2/CHP did not associate with loss of body weight. Furthermore, only a single application of PGE2 in combination with nanogel cross-linking hydrogel sphere (PGE2/CHP-PEO) induced new bone formation. Thus, nanogel-based delivery system is an efficient delivery system of bone anabolic agent, PGE2. J. Cell. Biochem. 101:1063–1070, 2007.Keywords
This publication has 19 references indexed in Scilit:
- Design of Hybrid Hydrogels with Self-Assembled Nanogels as Cross-Linkers: Interaction with Proteins and Chaperone-Like ActivityBiomacromolecules, 2005
- The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting bone morphogenetic protein–induced bone formationThe Journal of Experimental Medicine, 2005
- Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapyNature Medicine, 2005
- A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2Biochemical and Biophysical Research Communications, 2004
- Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature ratsBone, 2004
- A Novel, Non-Prostanoid EP2 Receptor-Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture HealingJournal of Bone and Mineral Research, 2003
- Repair of bone defects using synthetic mimetics of collagenous extracellular matricesNature Biotechnology, 2003
- Enhancing Effect of Tob Deficiency on Bone Formation Is Specific to Bone Morphogenetic Protein-Induced OsteogenesisJournal of Bone and Mineral Research, 2002
- Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activationProceedings of the National Academy of Sciences, 2002
- Self-aggregates of hydrophobized polysaccharides in water. Formation and characteristics of nanoparticlesMacromolecules, 1993